JP2021536239A5 - - Google Patents

Info

Publication number
JP2021536239A5
JP2021536239A5 JP2021510744A JP2021510744A JP2021536239A5 JP 2021536239 A5 JP2021536239 A5 JP 2021536239A5 JP 2021510744 A JP2021510744 A JP 2021510744A JP 2021510744 A JP2021510744 A JP 2021510744A JP 2021536239 A5 JP2021536239 A5 JP 2021536239A5
Authority
JP
Japan
Prior art keywords
rna
oligonucleotide
abnormal
pharmaceutical composition
peptide epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536239A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/072898 external-priority patent/WO2020043750A1/en
Publication of JP2021536239A publication Critical patent/JP2021536239A/ja
Publication of JP2021536239A5 publication Critical patent/JP2021536239A5/ja
Pending legal-status Critical Current

Links

JP2021510744A 2018-08-28 2019-08-28 スプライス調節化合物を使用したネオアンチゲン操作 Pending JP2021536239A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18191271 2018-08-28
EP18191271.8 2018-08-28
EP18194983.5 2018-09-18
EP18194983 2018-09-18
EP19178168.1 2019-06-04
EP19178168 2019-06-04
PCT/EP2019/072898 WO2020043750A1 (en) 2018-08-28 2019-08-28 Neoantigen engineering using splice modulating compounds

Publications (2)

Publication Number Publication Date
JP2021536239A JP2021536239A (ja) 2021-12-27
JP2021536239A5 true JP2021536239A5 (https=) 2022-09-01

Family

ID=67742445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510744A Pending JP2021536239A (ja) 2018-08-28 2019-08-28 スプライス調節化合物を使用したネオアンチゲン操作

Country Status (5)

Country Link
US (1) US20220160870A1 (https=)
EP (1) EP3844274A1 (https=)
JP (1) JP2021536239A (https=)
CN (1) CN113728102A (https=)
WO (1) WO2020043750A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3918069A1 (en) * 2019-01-31 2021-12-08 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
WO2023235838A2 (en) * 2022-06-02 2023-12-07 Skyhawk Therapeutics, Inc. Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases
CN118615431A (zh) * 2023-03-08 2024-09-10 广州医科大学 一种抗原表位在制备治疗肿瘤的产品中的应用
CN118620958A (zh) * 2023-03-08 2024-09-10 广州医科大学 一种抗原表位的制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
WO2004046160A2 (en) 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
AU2005206389A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US8501703B2 (en) 2005-08-30 2013-08-06 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
WO2007058894A2 (en) 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
EP2445538A2 (en) * 2009-06-23 2012-05-02 University Of Miami Aptamer-targeted sirna to inhibit nonsense mediated decay
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
GB201219762D0 (en) * 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014080381A1 (en) * 2012-11-26 2014-05-30 Ecole Polytechnique Federale De Lausanne (Epfl) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
CA2935426C (en) 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
CN106795200B (zh) 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
EP3234134B1 (en) 2014-12-17 2020-05-27 ProQR Therapeutics II B.V. Targeted rna editing
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3323890A4 (en) 2015-07-14 2019-01-30 Fukuoka University METHOD OF INDUSTRYING SITE-SPECIFIC RNA MUTATIONS, TARGETED EDITING GUIDE RNA USED IN THE METHOD AND TARGET RNA TARGET EDITING GUIDE RNA COMPLEX
US11458097B2 (en) 2016-03-30 2022-10-04 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
CN110352244B (zh) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
US11820981B2 (en) * 2016-09-14 2023-11-21 Agency For Science, Technology And Research Modulation of TJP1 expression to regulate regeneration of heart cells
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
WO2018141027A1 (en) * 2017-02-03 2018-08-09 The University Of Western Australia Novel treatment for neat1 associated disease
CN110612353A (zh) 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
WO2018208998A1 (en) 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
KR102761791B1 (ko) * 2017-06-26 2025-02-05 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법
US10476825B2 (en) * 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
WO2019071274A1 (en) 2017-10-06 2019-04-11 Oregon Health & Science University Compositions and methods for editing rna
US20200332272A1 (en) 2017-10-23 2020-10-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing

Similar Documents

Publication Publication Date Title
JP2021536239A5 (https=)
TWI722657B (zh) 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
ES2883335T3 (es) Métodos y composiciones para el diagnóstico y tratamiento del glioblastoma
Thongchot et al. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy
JP2018502120A5 (https=)
JP2019511222A5 (https=)
JP2014509841A5 (https=)
WO2019135701A1 (en) Endogenous tumor-derived circular rna and proteins thereof for use as vaccine
Tan et al. mRNA vaccine-A new cancer treatment strategy
JP2024105526A (ja) 免疫応答を誘導するための組成物
Lin et al. The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
JP2022539157A5 (https=)
CN114929275A (zh) 使用dkk-1抑制剂治疗癌症的方法
WO2017115798A1 (ja) 腫瘍抗原ペプチド
JP2021505190A5 (https=)
Zhang et al. A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research
CN115028738B (zh) 一种Fc融合蛋白双重靶向降解剂及应用
JP2002284797A (ja) サバイビン由来癌抗原ペプチド
JP2025500926A5 (https=)
Hendrickson et al. Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
Geng et al. Adenovirus-based strategies for cancer vaccines
WO2023049921A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
CN115212300A (zh) 一种用于肝癌免疫治疗的组合物及其应用
CN121064280A (zh) 一种抗肝癌hla-a*02型疫苗及其制备方法和应用